Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis | Zendy

Gauree G. Konijeti | Zendy; Jenny Sauk | Zendy; Mark G. Shrime | Zendy; Meera Gupta | Zendy; Ashwin N. Ananthakrishnan | Zendy

Open Access

Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis

Author(s) -

Gauree G. Konijeti,

Jenny Sauk,

Mark G. Shrime,

Meera Gupta,

Ashwin N. Ananthakrishnan

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu128

Subject(s) - fidaxomicin , medicine , clostridium difficile , colonoscopy , metronidazole , cost effectiveness , population , intensive care medicine , surgery , vancomycin , antibiotics , colorectal cancer , risk analysis (engineering) , environmental health , cancer , biology , bacteria , microbiology and biotechnology , genetics , staphylococcus aureus

Clostridium difficile infection (CDI) is an important cause of morbidity and healthcare costs, and is characterized by high rates of disease recurrence. The cost-effectiveness of newer treatments for recurrent CDI has not been examined, yet would be important to inform clinical practice. The aim of this study was to analyze the cost effectiveness of competing strategies for recurrent CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research